Drug Trial Radar · NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 13, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- 858 Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
Conditions
- Advanced or Metastatic Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Epithelial Ovarian Cancer
- BRCA2 Mutation
- ER+ Breast Cancer
- Castrate Resistant Prostate Cancer
- BRCA1 Mutation
- BRCA Mutation
- Endometrial Cancer
- Colorectal Cancer
- Gastric Cancer
Interventions
ETX-19477Drug
Oral medication taken daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477Time frame: 6 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut · Recruiting
Mayo Clinic
Jacksonville, Florida · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio · Recruiting
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
START Center for Cancer Care - Mountain Region
Salt Lake City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.